With 5 currently approved PI3K inhibitors in the market, and countless investments, M&As and candidates entering the clinical stages, the PI3K pathways space has experienced significant growth in recent years.
The inaugural PI3K Pathways Summit is the industry’s only definitive conference providing in depth exploration of the biochemical basis of the pathway, the successes and setbacks in gaining approval for PI3K inhibitors and the future advances which will potentially aid in overcoming issues with tolerability, toxicity and resistance associated with PI3K inhibitors.
Join the online discussion at the only digital platform dedicated to bringing together the community of PI3K experts from large pharma, innovative biotechs and research institutes for a unique opportunity to address the challenges of targeting the PI3K and AKT pathway, evaluate strategies for overcoming these challenges to define next generation PI3K drugs and participate in cross-disciplinary discussions with fellow industry peers.
Time: 9:00 am - 5:00 pm
Conference + 2 Workshops - Drug Developers: USD 2797.00,
Conference + 1 Workshop - Drug Developers: USD 2448.00,
Conference Only - Drug Developers: USD 2099.00,
Conference + 2 Workshops - Acdemics: USD 1647.00,
Conference + 1 Workshop - Academics: USD 1498.00,
Conference Only - Academics: USD 1349.00,
Conference + 2 Workshops - Service Providers: USD 3397.00,
Conference + 1 Workshop - Service Providers: USD 2998.00,
Conference Only - Service Providers: USD 2599.00
Speakers: Zoe Johnson, Chief Scientific Officer, iOnctura, James Garner, Chief Executive Officer and Managing Director, Kazia Therapeutics, Lewis Cantley, Director Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, Nishan Rajakumaraswamy, Director, Clinical Research, Oncology/ Hematology, Gilead Sciences, George Poulogiannis, Team Leader, Signaling and Cancer Metabolism, The Institute of Cancer Research, Harish Dave, Chief Medical Officer, AUM Biosciences, Philip Beer, Head of Research and Translational Medicine, Karus Therapeutics, Bart Vanhaesebroeck, Professor of Cell Signaling, UCL, Thomas Rossi, Chief Executive Officer, Venthera, Ewen Munro, Director Medical and Scientific Affairs, Pharming Group, Sathish Padi, Scientist III, The University of Arizona, Klaus Okkenhaug, Professor of Immunology, University of Cambridge, Jochen Lorch MD, Medical Oncology, Dana-Farber Cancer Institute, Priyanka Tibarewel, Research Assistant, UCL, Teresa Gagliano, Tenure-Track Assistant Professor, University of Udin, Igor Vivanco, Team Leader - Molecular Addictions, Institute of Cancer Research, Markus Muschen, Professor of Hematology Director, Center of Molecular and Cellular Oncology, Arthur H. and Isabel Bunker, Yale University